Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 1.1% year on year to $233.4 million. On the other hand, next quarter’s revenue guidance of $235 million was less impressive, coming in 2.4% below analysts’ estimates. Its non-GAAP profit of $0.74 per share was 9.9% above analysts’ consensus estimates.

Is now the time to buy Novanta? Find out in our full research report.

  • Revenue: $233.4 million vs analyst estimates of $233.3 million (1.1% year-on-year growth, in line)

  • Adjusted EPS: $0.74 vs analyst estimates of $0.67 (9.9% beat)

  • Adjusted EBITDA: $49.98 million vs analyst estimates of $50.21 million (21.4% margin, in line)

  • Revenue Guidance for Q2 CY2025 is $235 million at the midpoint, below analyst estimates of $240.7 million

  • Adjusted EPS guidance for Q2 CY2025 is $0.73 at the midpoint, below analyst estimates of $0.75

  • EBITDA guidance for Q2 CY2025 is $52.5 million at the midpoint, in line with analyst expectations

  • Operating Margin: 13.9%, up from 12.1% in the same quarter last year

  • Free Cash Flow Margin: 11.7%, similar to the same quarter last year

  • Market Capitalization: $4.32 billion

Originally a pioneer in the laser scanning industry during the late 1960s, Novanta (NASDAQ:NOVT) offers medicine and manufacturing technology to the medical, life sciences, and manufacturing industries.

Examining a company’s long-term performance can provide clues about its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last five years, Novanta grew its sales at a decent 8.8% compounded annual growth rate. Its growth was slightly above the average industrials company and shows its offerings resonate with customers.

Novanta Quarterly Revenue
Novanta Quarterly Revenue

We at StockStory place the most emphasis on long-term growth, but within industrials, a half-decade historical view may miss cycles, industry trends, or a company capitalizing on catalysts such as a new contract win or a successful product line. Novanta’s recent performance shows its demand has slowed as its annualized revenue growth of 4.2% over the last two years was below its five-year trend. We also note many other Electronic Components businesses have faced declining sales because of cyclical headwinds. While Novanta grew slower than we’d like, it did do better than its peers.

Novanta Year-On-Year Revenue Growth
Novanta Year-On-Year Revenue Growth

This quarter, Novanta grew its revenue by 1.1% year on year, and its $233.4 million of revenue was in line with Wall Street’s estimates. Company management is currently guiding for flat sales next quarter.